详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China [2]Shanghai Chest Hosp, Shanghai, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China [4]Shanghai Chest Hosp, Dept Pathol, Shanghai, Peoples R China

出处：

DOI：

ISSN：

关键词： PD-1 inhibitor multi-target angiogenesis agent advanced NSCLC

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2017]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 10.34 出版当年[2017版] 7.296 出版当年五年平均 6.595 出版前一年[2016版] 12.46 出版后一年[2018版]

第一作者：

第一作者单位： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial [2]Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes. [3]Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation [4]A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC [5]Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes (vol 13, 836958, 2022) [6]Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients [7]Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer [8]Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient [9]PD-1抑制剂治疗慢性活动性EB病毒感染6例报告并文献复习 [10]A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer